Carotid body tumor secondary prevention

Jump to navigation Jump to search

Carotid body tumor Microchapters


Patient Information


Historical Perspective




Differentiating Carotid Body Tumor from other Diseases

Epidemiology and Demographics

Risk Factors


Natural History, Complications and Prognosis


Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings



Echocardiography and Ultrasound

CT scan


Other Imaging Findings

Other Diagnostic Studies


Medical Therapy


Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Carotid body tumor secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Carotid body tumor secondary prevention

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical

US National Guidelines Clearinghouse

NICE Guidance

FDA on Carotid body tumor secondary prevention

CDC on Carotid body tumor secondary prevention

Carotid body tumor secondary prevention in the news

Blogs on Carotid body tumor secondary prevention

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Carotid body tumor secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sahar Memar Montazerin, M.D.[2] Maria Fernanda Villarreal, M.D. [3]


There is insufficient evidence to recommend routine screening for the carotid body tumor. However, patients who manifested the symptoms before the age of 50 years old, those with a positive family history and those with multiple paragangliomas has been recommended to undergo additional testing.


Patient with carotid body tumor
History, Physical examination, and evaluation of cnotralateral side
Patients with age < 50 years
Patients with multiple paraganglioma
Patients with a positive family history
The rest of the patients
SDHD genetic testing
Presence of SDHD mutation
Absence of SDHD mutation
SDHC and SDHB genetic testing
Presence of SDHC/SDHB mutation
Absence of SDHC/SDHB mutation
All the relatives should be evaluated for the presence of paragnaglioma
whole-body F-dihydroxyphenylalanine (F-DOPA) positron emission tomography to assess the presence of other paragangliomas
Presence of other paraganglioma
Absence of other paraganglioma
24-hour urine catecholamines and MRI for biochemical screening
surveillance screening every 5 years


  1. Davila, Victor J.; Chang, James M.; Stone, William M.; Fowl, Richard J.; Bower, Thomas C.; Hinni, Michael L.; Money, Samuel R. (2016). "Current surgical management of carotid body tumors". Journal of Vascular Surgery. 64 (6): 1703–1710. doi:10.1016/j.jvs.2016.05.076. ISSN 0741-5214.